



February 24, 2005

Celsion to Hold Quarterly Conference Call Thursday, March 3, 2005

COLUMBIA, Md.--(BUSINESS WIRE)--Feb. 24, 2005--CELSION CORPORATION (AMEX:CLN) announced today that it would hold its regular quarterly shareholders' conference call at 11:00 a.m. Eastern Time on Thursday, March 3, 2005. To participate in the call, interested parties can dial 800.510.0178 (domestic) or 617.614.3450 (international), access code: 37980523 to register ten minutes before the call is scheduled to begin.

The call will be archived for replay on Thursday, March 3, 2005 at 1:00 p.m. until Thursday, March 10, 2005. The replay can be accessed at 888.286.8010 (domestic) or 617.801.6888 (international) access code: 82397859. The call will also be available on the Company's website, <http://www.celsion.com> for 90 days after 1:00 p.m. on Thursday, March 3, 2005.

ABOUT CELSION: Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of treatment systems for cancer and other diseases using focused-heat energy in combination with other therapeutic devices, heat-activated genes and heat-activated drugs.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: <http://www.celsion.com/>.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

CONTACT: Celsion Corporation, Columbia
Tony Deasey, 410-290-5390
tony@celsion.com
or
General Info:
Financial Relations Board
Marilynn Meek, 212-827-3773
mmeek@financialrelationsboard.com
or
Investor Info:
Susan Garland, 212-827-3775
sgarland@financialrelationsboard.com

SOURCE: Celsion Corporation